K
Description
Clinical-stage biopharmaceutical company founded in 2020 in Boston, Massachusetts. Develops frevecitinib (KN-002), an inhaled pan-JAK inhibitor for severe and inadequately controlled asthma. Closed a $103 million oversubscribed Series B round in January 2026.